



Dr méd. Yordanka Tirefort

Specialist in onco-hematology, general hematology, hemostasis (bleeding disorders and thrombophilia) and General Internal Medicine, FMH member

Profile

Languages

Français, anglais, bulgare

Work experience

2018	Chief physician of the Department of Hematology and Haemostasis, Diagnostic Laboratory SYNLAB Switzerland SA, Western Switzerland
since 2018	Independent haematologist
2016-2018	Attending haematologist (chef de clinique), in charge of outpatient follow-up of patients received bone marrow transplantation
since 2016	Medical Director of the Cord Blood Bank at the University Hospitals of Geneva, Switzerland (HUG)
2016-2018	Head of the Haematopoietic Stem Cell Lab, Department of Medical Diagnostics, HUG. Promoted from the position of Medical Director (2016-2013)
2015	Post-doc fellowship on the GMP practices with the Department of Hematology and the Center José-Carreras for Interventional Immunology, University Hospital of Regensburg, Germany
2012-2018	Attending haematologist (chef de clinique), Department of Haematology, HUG.
2008-2012	Resident at the Department of Haematology and the Angiology and Haemostasis Unit, HUG
2008-2003	Resident at the Departments of Internal Medicine and the Department of Rehabilitation
2001-2003	Research Assistant at the Angiology and Haemostasis Unit, HUG
1998-2001	Medical Research Associate, Laboratory of Immuno-haematology, Department for Immuno-haematology and Blood Transfusion of the National Center for Oncology and Haematology, Sofia, Bulgaria

Education

2018	DAS (Diploma of Advanced Studies) - Management of Clinical Trials, Faculty of Medicine, University of Geneva
2016	Clinical research investigator (GCP-ICP) Certificate.
2016	Federal diploma FAMH Specialist in Laboratory Haematological Analyses
2012	Federal diploma FMH Specialist in Hematology

2010	Post-doc diploma in the Diseases of Hemostasis from the Medical Faculty at the University of Montpellier, France.
2009	Federal diploma FMH Specialist in Internal Medicine
2003	Doctor in Medicine (MD)
1997	Medical degree with mention

Memberships

- European Hematology Association
- Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)
- National Commission Swisscord- Schweizerisches Rotes Kreuz
- International Cord Blood Association
- FMH
- AMGE
- SVM

Enseignement

2014-2018	Tuteur des étudiants de troisième année de médecine de l'Université de Genève pour les travaux pratiques dans l'unité « Défenses et immunité » En tant que chef de clinique du Service d'Hématologie, HUG, impliquée dans la formation des médecins internes en hématologie et la formation des équipes soignants prenant en charge des patients avec des pathologies hématologiques et des patients greffés de moelle.
-----------	--

Competences

- Oncologie hématologique (lymphome, myélome, leucémie, néoplasie myéloproliférative, etc.)
- Troubles hématologiques bénins, troubles du métabolisme en fer etc.
- Greffe de moelle osseuse, complications post-greffe (infections, maladie greffe contre hôte -GvHD, etc.)
- Hémostase - troubles hémorragiques et thrombophilie
- Analyses de laboratoire en hématologie ; transfusion sanguine et procédures d'hémovigilance

Publications

1. Blum S; Dunet V, Comoli P, Tirefort Y,... Du Pasquier R. Progressive Multifocal Leukoencephalopathy Responsive to Withdrawal of Imatinib in a Patient with FIP1L1-PDGFRA Positive Myeloid Neoplasm. *Leuk and Lymphoma*. 2020;61:2226.
2. Tirefort Y. et Buser-Llinares R. Le don de sang de cordon sauve des vies. *Obstetrica* 2019, 3: 8-11.
3. Simonetta F, Pradier A , Bosshard C, Masouridi-Levrat S , Carole D , , Tirefort Y, Roosnek E, Chalandon Y. Dynamics of Expression of Programmed Cell Death Protein-1 (PD-1) on T Cells After Allogeneic Hematopoietic Stem Cell Transplantation. *Front Immunol*. 2019;10:1034.
4. Tirefort Y. et Buser- Llinares R. Le don de sang de cordon sauve des vies. *Obstetrica* 2019, 3: 8-11.

5. Brissot E, Alsuliman T, Gruson B, Hermet Eric , Tirefort Y, Yakoub-Agha I, Alain S. Conduite à tenir devant une réactivation EBV et un syndrome lymphoprolifératif à EBV, une réactivation ou infection à CMV et à HHV-6 après allogreffe de cellules souches hématopoïétiques : recommandations de la SFGM-TC (mises à jour) [How to manage EBV reactivation and EBV-PTLD, CMV and human herpesvirus 6 reactivation and infection after allogeneic stem cell transplantation: A report of the SFGM-TC (update)]. *Bull Cancer*. 2017;104(12S):S181-S187.
6. Masouridi-Levrat S, Simonetta F, Beauverd Y, Tsopra O, Tirefort Y...,Chalandon Y. Excellent outcome with a high proportion of mixed chimerism in patients with severe aplastic anemia treated with partially T-cell-depleted peripheral hematopoietic stem cell transplants. *Bone Marrow Transplant*. 2016;51(6):860-862.
7. Raboud M,.... Tirefort Y, Masouridi-Levrat S, Chalandon Y. Impact of T-cell depletion on outcome of patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome. *Bone Marrow Transplant*. 2018;53(8):1072-1075. 2
8. Paiano S, Roosnek E, Tirefort Y,....,Chalandon Y. Comparing Two Types of Rabbit ATG prior to Reduced Intensity Conditioning Allogeneic Hematopoietic SCT for Hematologic Malignancies. *Bone Marrow Research* 2015.
9. Simonetta F, Guerne PA, Tirefort Y,...., Chalandon Y. Complete and sustained remission of spondyloarthritis after allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome. *Joint Bone Spine*. 2014.
10. Beauverd Y, Roosnek E, Tirefort Y,...., Chalandon Y. Validation of the Disease Risk Index for Outcome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation after T Cell Depletion. *Biol Blood Marrow Transplant*. 2014; 20: 1322.
11. Tirefort Y, Pham XC,...., Samii K. A rare case of primary cutaneous follicle centre lymphoma presenting as a giant tumor of the scalp and combined with JAK2V617F positive essential thrombocythaemia. *Biomark Res*. 2014; 2: 7-12.
12. Tirefort Y, de Moerloose P, Neerman-Arbez M. Mutation of the translation initiation codon in FGA causes congenital afibrinogenaemia. *Blood Coagul Fibrinolysis*. 2012, 23: 556-558.
13. Tirefort Y, Uhr MR, Neerman-Arbez M, de Moerloose P. Identification of a novel F11 missense mutation (Ile463Ser) in a family with congenital factor XI deficiency. *Blood Coagul Fibrinolysis*. 2012, 23: 251-252.
14. Neerman-Arbez M, Tirefort Y, Moerloose P. Can mutations identified in congenital fibrinogen disorders explain the clinical manifestations? *J of Coagulation Disorders*, 2010; 2(2): 71-79.
15. Boehlen F, Tirefort-Dimitrova Y, de Moerloose P, Fontana P. Hémostase le point sur les nouveaux antithrombotiques. *Rev Médi Suisse*, 2010 Jan 20; 6 (232): 109-12.
16. de Moerloose P, Tirefort-Dimitrova Y,...., Boehlen F. Syndrome des anticorps antiphospholipides : beaucoup de nouveautés. *Rev Méd Suisse*, 2010 Feb 10; 6 (235): 298-301.
17. Dunoyer- Geindre S, Dimitrova Y (Tirefort),...., de Moerloose P. Fluvastatin increases the expression of adhesion molecules, MCP-1 and tissue factor in HUVEC stimulated by antiphospholipid antibodies. *J Thrombosis and Hemostasis* 2005; 93(2): 339-45.
18. Dimitrova Y (Tirefort), Geindre S,...., de Moerloose P. Effects of statins on adhesion molecule expression in endothelial cells. *J Thromb and Hemostasis* 2003(1): 2990-2999.

19. De Moerloose P, Dimitrova Y (Tirefort),..., Boehlen F. Maladie thrombo-embolique veineuse et thrombophilie: quel bilan demander pour quelles implications cliniques. Médecine et Hygiène 2002; S16-S20.
20. Regazzoni S, Luzuy F, Dimitrova Y (Tirefort), de Moerloose P. La protéine C: un nouveau traitement pour les sepsis et les méningococcémies sévères. Médecine et Hygiène 2002; 60: 42-46.
21. Dimitrova Y (Tirefort). Competitive assessment of the methods, used for the diagnosis of Immune Thrombopenic Purpura. Annual Proceeding International Medical Association 2000; 6: 189-191.
22. Dimitrova Y (Tirefort), Kalev I. Immune Thrombocytopenic Purpura - diagnosis and therapeutic approaches. General Medicine 2000; 2: 32-38.

Awards

Winner of **2004** best thesis in fundamental medicine from the Faculty of Medicine of the University of Geneva. The thesis was entitled “The effects of the statins on the endothelial cells activation by the antiphospholipid antibodies”.

Handouts Presentations

1. Tirefort Y, Simonetta F,..., Chalandon Y. Impact of the different approaches of T cell depletion on NK cell subsets reconstitution after allogeneic Hematopoietic Stem Cell Transplantation EBMT 2015, Istanbul, P674.
2. Tirefort Y, Hauwel M,..., Matthes T. Multiparameter flow cytometry (MPFC): role in diagnosis and follow-up of patients with plasma cell diseases, European and Swiss congress ESCIM 2014, Geneva, abstract Nr. A-648-0008-0093.
3. Tirefort Y, Pham X-C,..., Samii K. A rare case of association of primary cutaneous follicle centre lymphoma presenting as a giant tumor of the scalp and essential thrombocythaemia, 81e assemblée de la SSMI/SSH 2013, Bâle, P 464.
4. Tirefort Y, Roosnek E,..., Chalandon Y. Prognostic significance of EBMT risk score for the outcome of allogeneic hematopoietic stem cell transplantations after T-cell depletion. Communication orale SSH 2012.
5. Paiano S, Roosnek E, Tirefort Y,..., Chalandon Y. A study comparing two types of rabbit ATG as part of pre-transplant conditioning for allogeneic HSCT for hematologic malignancies: Earlier relapse with Thymoglobulin as compared to ATG-F. EBMT 2011.
6. Dimitrova Y (Tirefort), Dunoyer-Geindre S, Kruithof E, Reber G, de Moerloose P. Effects of statins on adhesion molecules expression in endothelial cells. XIX Congress of the International Society on Thrombosis and Haemostasis. Birmingham, UK. P0155, ref. 4415.
7. Dunoyer-Geindre S, Dimitrova Y (Tirefort), Kruithof EKO, Reber G, de Moerloose P. Effects of statins on endothelial activation by tumor necrosis factor. X International Congress on Antiphospholipid Antibodies. Sicile, Italie. Lupus 2002; 11: 590.
8. Dimitrova Y (Tirefort). Recurrent anti-HPA-Ia induced neonatal allo-immune thrombocytopenia in one family. Congrès de la Société française de Thrombose et Hémostase, Genève, 2001.

Accreditation

[Générale-Beaulieu Swiss Oncology Network](#)

[Clinique Générale-Beaulieu](#)

[Clinique de Genolier](#)

Specialties

[Haematology](#)

[Oncology](#)

Contact

Générale-Beaulieu Swiss Oncology Network
Chemin de Beau-Soleil 20
1206 Genève

T +41 22 839 57 83

F +41 31 930 22 02

ytirefort@beaulieu.ch

[Download vCard](#)

Clinique de Genolier
Route du Muids 3
1272 Genolier

ytirefort@genolier.net

[Download vCard](#)